Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AntagoBrad: C1 inhibitor and icatibant for COVID-19 pulmonary manifestations
NCT05010876Phase 2Completed
- Sponsor
- Ramsay Santé
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Human C1-esterase inhibitor, icatibant in coronavirus disease 2019 (COVID-19), sponsored by Ramsay Santé. Started Feb 2021; status: completed.
02
Drugs
Human C1-esterase inhibitoricatibant
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05010876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010876.